MedTrace Logo

A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

NCT06007846 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-09-30

No results posted yet for this study

Summary

This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.

Conditions

Interventions

DRUG

Namenda

Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily

Sponsors & Collaborators

  • Inova Health Care Services

    lead OTHER

Principal Investigators

  • Arthur Winer, MD · Inova Health Care Service

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-31
Primary Completion
2026-07-31
Completion
2026-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06007846 on ClinicalTrials.gov